NEW YORK and LONDON, January 27, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Press Release
Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
NEW YORK and LONDON, January 5, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced an update …
Akari Therapeutics Announces Update from Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
NEW YORK and LONDON, December 7, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, provided an update …
Akari Therapeutics Announces Upcoming Data Presentations at the 57th American Society of Hematology Annual Meeting
NEW YORK and LONDON, November 5, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Akari Therapeutics Closes $75 Million Private Placement
NEW YORK and LONDON, September 21, 2015 AAkari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX), an emerging growth, …
[Read more...] about Akari Therapeutics Closes $75 Million Private Placement
